Found 360 results
Author Keyword Title Type [ Year(Asc)]
E. Eisenhauer, Addressing unanswered questions in ovarian cancer trial methodology: follow-up of the 2004 Baden-Baden Gynecologic Cancer Intergroup meeting., Int J Gynecol Cancer, vol. 18 Suppl 1, pp. 74-5, 2008.
W. Small, Mell, L. K., Anderson, P., Creutzberg, C., Santos, J. De Los, Gaffney, D. K., Jhingran, A., Portelance, L., Schefter, T., Iyer, R., Varia, M., Winter, K., and Mundt, A. J., Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer., Int J Radiat Oncol Biol Phys, vol. 71, no. 2, pp. 428-34, 2008.
S. V. Barrett, Paul, J., Hay, A., Vasey, P. A., Kaye, S. B., Glasspool, R. M., and Group, S. Gynaecolog, Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial, Ann Oncol, vol. 19, pp. 898-902, 2008.
G. C. E. Stuart, Future opportunities of the Gynecological Cancer Intergroup, Int J Gynecol Cancer, vol. 18 Suppl 1, pp. 71-3, 2008.
G. C. E. Stuart, Future opportunities of the Gynecological Cancer Intergroup., Int J Gynecol Cancer, vol. 18 Suppl 1, pp. 71-3, 2008.
E. Åvall-Lundqvist, Wimberger, P., Gladieff, L., Gebski, V., Huober, J., Floquet, A., Fitzharris, B., Zeimet, A. G., Heywood, M., and Schmalfeldt, B., Pegylated liposomal doxorubicin-carboplatin vs paclitaxel-carboplatin in relapsing sensitive ovarian cancer: a 500-patient interim safety analysis of the CALYPSO GCIG intergroup phase III study. , Proc.Am.Soc.Clin.Oncol. , vol. 26, no. 15S Part I, 2008.
P. A. Vasey, Gore, M. E., Wilson, R. H., Rustin, G. J. S., Gabra, H., Guastalla, J. P., Lauraine, E. P., Paul, J., Carty, K., Kaye, S. B., and Group, S. Gynaecolog, A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers, Br J Cancer, vol. 98, pp. 1774-80, 2008.
T. J. Herzog, Powell, M. A., Rader, J. S., Gibb, R. K., Lippmann, L., Coleman, R. L., and Mutch, D. G., Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer., Gynecol Oncol, vol. 111, no. 3, pp. 467-73, 2008.
S. Pignata, Breda, E., Scambia, G., Pisano, C., Zagonel, V., Lorusso, D., Greggi, S., De Vivo, R., Ferrandina, G., Gallo, C., and Perrone, F., A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study, Crit Rev Oncol Hematol, vol. 66, pp. 229-36, 2008.
N. Simon Reed, Mangioni, C., Malmström, H., Scarfone, G., Poveda, A. M., Pecorelli, S., Tateo, S., Franchi, M., Jobsen, J. J., Coens, C., Teodorovic, I., Vergote, I. B., and Vermorken, J. B., Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)., Eur J Cancer, vol. 44, no. 6, pp. 808-18, 2008.
P. Hoskins, Vergote, I. B., Stuart, G. C. E., Cervantes, A., Tu, D., Carey, M. S., Provencher, D. M., Katsaros, D., P, G., and Eisenhauer, E., A phase III trial of cisplatin plus topotecan followed by paclitaxel plus carboplatin versus standard carboplatin plus paclitaxel as first-line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer (OV.16). A GCIG Study., Proc.Am.Soc.Clin.Oncol. , vol. 26, no. 15S Part I, 2008.
L. Verleye, Coens, C., Amant, F., van der Burg, M. E. L., Johnson, N., Verheijen, R. H. M., Coronado, P., Reed, N. Simon, RJ, P., and Vergote, I. B., Predictive value of C-ERB2 for response to first-line chemotherapy in 206 advanced-stage ovarian cancer patients. , Int Gyn Cancer Soc, 2008.
M. S. Carey, Bacon, M., Tu, D., Butler, L., Bezjak, A., and Stuart, G. C. E., The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer., Gynecol Oncol, vol. 108, no. 1, pp. 100-5, 2008.
G. Ferrandina, Ludovisi, M., Corrado, G., Carone, V., Petrillo, M., and Scambia, G., Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer, Gynecol Oncol, vol. 109, pp. 187-93, 2008.
L. Verleye, PB, O., Coens, C., Amant, F., Kristensen, G. B., Tropé, C. G., Johnson, N., HC, vanDoorn, Reed, N. Simon, Verheijen, R. H. M., Hoskins, P., Trimbos, B., B, M., Mendiola, C., J, vander Velden, Eisenhauer, E., and Vergote, I. B., Quality of surgery in advanced ovarian cancer: Audit of original surgery reports of 442 patients from the neoadjuvant trial. , Int Gyn Cancer Soc, 2008.
R. Osborne, Filiaci, V. L., J, S., Mannel, R., Lage, J., A, A. - S., J, K., Provencher, D. M., Schilder, R. J., and Miller, D. S., A randomized phase III trial comparing weekly parenteral methotrexate and "pulsed" dactinomycin as primary management for low-risk gestational trophoblastic neoplasia. , Society Gynecologic Oncologists, 2008.
N. Susumu, Sagae, S., Udagawa, Y., Niwa, K., Kuramoto, H., Satoh, S., Kudo, R., and Group, J. Gynecologi, Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study, Gynecol Oncol, vol. 108, pp. 226-33, 2008.
A. M. Poveda, Ten years of "Optimal Therapy in Advanced Ovarian Cancer. Update" meeting, Int J Gynecol Cancer, vol. 18 Suppl 1, pp. 67-70, 2008.
O. Tredan, Geay, J. - F., Touzet, S., Delva, R., Weber, B., Cretin, J., Provencal, J., Martin, J., Stefani, L., Pujade-Lauraine, E., Freyer, G., and Ovariens, Gd'Investig, Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Ann Oncol, vol. 18, pp. 256-62, 2007.
S. Kommoss, du Bois, A., Ridder, R., Trunk, M. J., Schmidt, D., Pfisterer, J., Kommoss, F., and -OVAR, A. G. O., Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaek, Br J Cancer, vol. 96, pp. 306-13, 2007.
I. Ray-Coquard, Paraiso, D., Guastalla, J. P., Leduc, B., Guichard, F., Martin, C., Chauvenet, L., Haddad-Guichard, Z., Lepille, D., Orfeuvre, H., Gautier, H., Castera, D., and Pujade-Lauraine, E., Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group, Br J Cancer, vol. 97, pp. 1200-5, 2007.
I. Cadron, Leunen, K., Amant, F., Van Gorp, T., Neven, P., and Vergote, I. B., The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer, Gynecol Oncol, vol. 106, pp. 354-61, 2007.
M. Leonard Friedlander, Buck, M., Wyld, D., Findlay, M., Fitzharris, B., De Souza, P., Davies, T., Kalimi, G., Allan, S., Perez, D., and Harnett, P., Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer, Int J Gynecol Cancer, vol. 17, pp. 350-8, 2007.
V. Möbus, Wandt, H., Frickhofen, N., Bengala, C., Champion, K., Kimmig, R., Ostermann, H., Hinke, A., Ledermann, J. A., -OVAR/AIO, A. G. O., and , Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT, J Clin Oncol, vol. 25, pp. 4187-93, 2007.
D. K. Gaffney, du Bois, A., Narayan, K., Reed, N. Simon, Toita, T., Pignata, S., Blake, P., Portelance, L., Sadoyze, A., Potter, R., Colombo, A., Randall, M., Mirza, M. R., and Trimble, E. L., Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG), Int J Radiat Oncol Biol Phys, vol. 68, pp. 485-90, 2007.